Central Nervous System

FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits

The US Food and Drug Administration (FDA) has placed a clinical hold on the Phase I trial of Neumora Therapeutics’…

Norgine seeks approval for high-risk neuroblastoma treatment

Norgine has sought approval for eflornithine (difluoromethylornithine [DFMO]) for the treatment of patients with high-risk neuroblastoma (HRNB). The development marks…

Lonza links with NeuroSense to detect exosome-based biomarkers

Swiss contract manufacturer Lonza and NeuroSense Therapeutics have partnered to detect exosome-based biomarkers to bolster diagnostics and treatments for neurodegenerative…

Seaport emerges after $100m raise with ex-Karuna team at helm

Seaport Therapeutics has entered the neuropsychiatry treatment space after emerging with $100m from a financing round. ARCH Venture Partners and…

FDA gives nod to BrainStorm for ALS trial after Phase III flop

BrainStorm Cell Therapeutics will be initiating a Phase IIIb confirmatory trial of its lead candidate NurOwn after discussions with the…

Acumen and Lonza to produce Alzheimer’s drug sabirnetug

Acumen Pharmaceuticals has entered a strategic partnership with Swiss contract manufacturer Lonza to further the development of sabirnetug (ACU193), a…

MiNA and Nippon Shinyaku enter RNAa therapeutics deal

MiNA Therapeutics has entered a research partnership and licensing agreement with Nippon Shinyaku to develop small activating RNA (RNAa) therapeutics…

Addex spinoff Neurosterix debuts with $63m for developing neurological therapies

Swiss company Neurosterix has launched into the neurological drug development scene with $63m in Series A funding to develop allosteric…

Otsuka and Lundbeck’s schizophrenia treatment gains EC approval

The European Commission (EC) has approved Otsuka Pharmaceutical Europe and H Lundbeck's Abilify Maintena 720mg/960mg (aripiprazole) for the maintenance treatment…

AriBio licenses Alzheimer’s pill in China for up to $770m

AriBio has signed off on exclusive marketing rights for its Alzheimer’s disease treatment candidate AR1001 in China. The deal, with…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close